程序性死亡蛋白-1抑制劑相關葡萄膜炎3例_Chinese Journal of Ocular Fundus Diseases

Authors：

葛瑤 ¹ , 李麗杰 ³ , 龐惠文 ¹ , 揭姍姍 ¹ , 邰仁清 ¹ , 高宏程 ² ,  陳晨 ² , 王偉 ²

1. ;
2. ;
3. ;

Corresponding?author：

陳晨, Email: sdchenchen@126.com

Keywords：

程序性死亡蛋白-1抑制劑; 葡萄膜炎; 藥物不良反應; 病例報告

DOI：

10.3760/cma.j.cn511434-20250630-00290

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

1.	Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461. DOI: 10.1016/j.ccell.2015.03.001.
2.	白日蘭, 崔久嵬. 免疫檢查點抑制劑治療相關不良反應——新探索、新挑戰[J]. 中國腫瘤生物治療雜志, 2021, 28(5): 419-430. DOI: 10.3872/j.issn.1007-385x.2021.05.001.Bai RL, Cui JW. Immune checkpoint inhibitor-related adverse events: New exploration and new challenges[J]. Chinese Journal of Cancer Biotherapy, 2021, 28(5): 419-430. DOI: 10.3872/j.issn.1007-385x.2021.05.001.
3.	Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461. DOI: 10.1016/j.ccell.2015.03.001.
4.	孫武, 茹姝婷, 史航, 等. 生物制劑誘發葡萄膜炎的研究進展[J]. 中國中醫眼科雜志, 2024, 34(5): 489-493. DOI: 10.13444/j.cnki.zgzyykzz.2024.05.021.Sun W, Ru ST, Shi H, et al. Research progress on biologic agents inducing uveitis[J]. Chinese Journal of Chinese Ophthalmology, 2024, 34(5): 489-493. DOI: 10.13444/j.cnki.zgzyykzz.2024.05.021.
5.	Xiao J, Wang S, Chen L, et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages[J]. Immunity, 2024, 57(5): 1087-1104. DOI: 10.1016/j.immuni.2024.03.021.
6.	Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes[J]. Ocul Immunol Inflamm, 2021, 29(1): 203-211. DOI: 10.1080/09273948.2020.1781902.
7.	Baughman DM, Lee CS, Snydsman BE, et al. Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma[J/OL]. Med Case Rep (Wilmington), 2017, 3(2): 8[2017-04-14]. https://pubmed.ncbi.nlm.nih.gov/28856338/. DOI: 10.21767/2471-8041.100044.
8.	Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma[J/OL]. Pharmacotherapy, 2016, 36(11): e183-e188[2016-10-26]. https://pubmed.ncbi.nlm.nih.gov/27716999/. DOI: 10.1002/phar.1839.
9.	Richardson DR, Ellis B, Mehmi I, et al. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report[J]. Int J Ophthalmol, 2017, 10(7): 1183-1186. DOI: 10.18240/ijo.2017.07.28.
10.	張書培, 楊磊, 顧康生. PD-1/PD-L1抑制劑治療晚期腫瘤患者免疫相關不良事件的預后價值[J]. 臨床腫瘤學雜志, 2022, 27(2): 109-116. DOI: 10.3969/j.issn.1009-0460.2022.02.003.Zhang SP, Yang L, Gu KS. Prognostic value of immune-related adverse events in patients with advanced tumors treated with PD-1/PD-L1 inhibitors[J]. Chinese Clinical Oncology, 2022, 27(2): 109-116. DOI: 10.3969/j.issn.1009-0460.2022.02.003.

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461. DOI: 10.1016/j.ccell.2015.03.001.
2. 白日蘭, 崔久嵬. 免疫檢查點抑制劑治療相關不良反應——新探索、新挑戰[J]. 中國腫瘤生物治療雜志, 2021, 28(5): 419-430. DOI: 10.3872/j.issn.1007-385x.2021.05.001.Bai RL, Cui JW. Immune checkpoint inhibitor-related adverse events: New exploration and new challenges[J]. Chinese Journal of Cancer Biotherapy, 2021, 28(5): 419-430. DOI: 10.3872/j.issn.1007-385x.2021.05.001.
3. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461. DOI: 10.1016/j.ccell.2015.03.001.
4. 孫武, 茹姝婷, 史航, 等. 生物制劑誘發葡萄膜炎的研究進展[J]. 中國中醫眼科雜志, 2024, 34(5): 489-493. DOI: 10.13444/j.cnki.zgzyykzz.2024.05.021.Sun W, Ru ST, Shi H, et al. Research progress on biologic agents inducing uveitis[J]. Chinese Journal of Chinese Ophthalmology, 2024, 34(5): 489-493. DOI: 10.13444/j.cnki.zgzyykzz.2024.05.021.
5. Xiao J, Wang S, Chen L, et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages[J]. Immunity, 2024, 57(5): 1087-1104. DOI: 10.1016/j.immuni.2024.03.021.
6. Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes[J]. Ocul Immunol Inflamm, 2021, 29(1): 203-211. DOI: 10.1080/09273948.2020.1781902.
7. Baughman DM, Lee CS, Snydsman BE, et al. Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma[J/OL]. Med Case Rep (Wilmington), 2017, 3(2): 8[2017-04-14]. https://pubmed.ncbi.nlm.nih.gov/28856338/. DOI: 10.21767/2471-8041.100044.
8. Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma[J/OL]. Pharmacotherapy, 2016, 36(11): e183-e188[2016-10-26]. https://pubmed.ncbi.nlm.nih.gov/27716999/. DOI: 10.1002/phar.1839.
9. Richardson DR, Ellis B, Mehmi I, et al. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report[J]. Int J Ophthalmol, 2017, 10(7): 1183-1186. DOI: 10.18240/ijo.2017.07.28.
10. 張書培, 楊磊, 顧康生. PD-1/PD-L1抑制劑治療晚期腫瘤患者免疫相關不良事件的預后價值[J]. 臨床腫瘤學雜志, 2022, 27(2): 109-116. DOI: 10.3969/j.issn.1009-0460.2022.02.003.Zhang SP, Yang L, Gu KS. Prognostic value of immune-related adverse events in patients with advanced tumors treated with PD-1/PD-L1 inhibitors[J]. Chinese Clinical Oncology, 2022, 27(2): 109-116. DOI: 10.3969/j.issn.1009-0460.2022.02.003.

Chinese Journal of Ocular Fundus Diseases

Latest Articles程序性死亡蛋白-1抑制劑相關葡萄膜炎3例

Abstract Full text Figures/Tables Video References Cited by

Format

Content